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Abstract 
Heart disease is the leading cause of morbidity and mortality in Americans with type 2 diabetes 
mellitus. The American Diabetes Association recommends statins and lifestyle modifications for 
all patients with type 2 diabetes mellitus for the prevention of atherosclerotic cardiovascular 
events. A patient-centered approach to primary prevention is encouraged, yet there are no 
specific instructions regarding implementation. The Statin Choice Decision Aid is a tool 
designed to facilitate shared decision-making between the patient and the provider in the clinical 
setting. The 2018 American College of Cardiology/American Heart Association guidelines for 
the primary prevention of atherosclerotic cardiovascular disease for patients with type 2 diabetes 
mellitus were implemented into practice by prescribing statins and patient education for the 
appropriate patients. The Statin Choice Decision Aid was integrated into the electronic health 
record and accessed by the provider during the clinical encounter with the patient to help guide 
the decision to initiate statin therapy.  Results yielded an impressive 82% increase in the 
provider’s statin prescribing practice. In addition, more than half (75%) of those patients had 
their individual atherosclerotic cardiovascular risk score computed and documented in the 
electronic health record. The Doctor of Nursing Practice quality improvement project helped to 
achieve optimal and patient-centered approach to successfully adhering to the American College 
of Cardiology/American Heart Association guidelines. 
Keywords: type 2 diabetes mellitus, cardiovascular disease, statins, shared decision-
making 
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Patient-Centered Implementation of Statin Therapy in Patients with Type 2 Diabetes 
Type 2 diabetes mellitus (T2DM) affects nearly 30 million Americans with 
approximately 1.5 million newly diagnosed cases every year (American Diabetes Association 
[ADA], 2018). The Texas Demographic Center (2018) estimates that 16.8% of the 2.3 million 
Texans living with diabetes mellitus reside in Laredo, Texas. As the number of cases of T2DM 
continues to rise, so does the occurrence of atherosclerotic cardiovascular disease (ASCVD). 
ASCVD is defined by the American Diabetes Association (ADA) as acute coronary syndrome, 
myocardial infarction, stroke, and peripheral vascular disease (National Library of Medicine, 
2018). The combination of T2DM and ASCVD is the leading cause of morbidity and mortality 
and can reduce the life expectancy of a person by about 12 years (Schmidt, 2019).  The 
cardiovascular-related expenditure associated with diabetes is valued at $37.3 billion per year 
(ADA, 2019). Evidence-based guidelines created by the American College of Cardiology (ACC) 
and American Heart Association (AHA) recommend statin therapy for lipid management and 
healthy lifestyle as first-line ASCVD prevention strategies in at-risk populations (Grundy et al., 
2018). In considering the use of statins for the treatment of ASCVD, a yearly assessment of the 
patient’s 10-year ASCVD risk score is important. This score considers the patient’s age, gender, 
race, comorbidities, blood pressure, and cholesterol levels. 
Simply prescribing statins to eligible patients is not always suitable or effective. The 
challenge emanates from the task of utilizing a patient-centered methodology. Ideally, the 
decision to begin statin therapy should start with a discussion between the patient and healthcare 
provider to identify and prioritize a patient’s values and preferences. This conversation, referred 
to as shared decision-making, allows the provider to explain the specifics of treatment in terms of 
benefits, harms, and costs and directly address patient questions (Serrano et al., 2016). Shared 
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decision-making is the cornerstone of patient-centered care and helps the provider to identify the 
patient’s social and financial attributes. Evidence-based tools have been developed to help 
clinicians use a shared decision-making approach to care in the form of education, choice, and 
conversation (Serrano et al., 2016). Mayo Clinic’s Statin Choice Decision Aid (SCDA) was 
specifically created with shared decision-making in mind. Using the patient’s data, the SCDA 
calculates the projected 10-year ASCVD risk score and by how much it can be decreased by 
initiating statin therapy (Inselman et al., 2016) (see Appendix A). Using the SCDA to make 
statin prescription decisions in a patient-centered manner can enhance both provider and patient 
satisfaction (Ye et al., 2018). 
Statement of the Problem 
Patients with T2DM are at higher risk of suffering an ASCVD event, such as a heart 
attack or stroke (Grundy et al., 2018). This risk is also increased by other factors, such as 
hyperlipidemia, hypertension, obesity, sedentary lifestyle and tobacco use (ADA, 2018).  The 
ACC and AHA explicitly mention the importance of patient-centered approach for the 
management of high cholesterol levels in adults with T2DM and ASCVD risk assessment for 
better health outcomes. Upon assessment of the microsystem, the clinic was found to be non-
compliant with recommendations made by the ACC and AHA.  
Background and Significance 
In addition to lifestyle changes, the clinical practice guidelines commissioned by the 
ACC/AHA (2018), recommend a moderate-intensity dose statin for the primary prevention of 
ASCVD in patients 40 to 75 years of age, with type 2 diabetes mellitus, a 10-year ASCVD risk 
score of greater than or equal to 7.5%, and a low-density lipoprotein cholesterol (LDL-C) level 
greater than or equal to 70 mg/dL (Grundy et al., 2018). Statins are a class of drugs that prevent 
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the production of cholesterol by the liver and help reduce cholesterol levels in the blood. Statin 
agents widely prescribed include atorvastatin, pravastatin, simvastatin, and rosuvastatin. The 
decision to prescribe a statin relies on the knowledge and expertise of practitioners. The advisory 
bodies, in addition to pharmacological treatment, recommend behavioral changes as the 
foundation of prevention of ASCVD in the diabetic population. These lifestyle behavioral 
changes include moderate-intensity aerobic exercise for a minimum of 150 min per week, 
limiting sodium intake, avoiding saturated fats, and increasing consumption of fruits, vegetables, 
and low-fat dairy products (Fox et al., 2015).  
Shared Decision-Making   
Shared decision-making allows clinicians to form an individualized care plan that fosters 
patient autonomy and shows respect. The three main components of shared decision-making are: 
(a) recognizing a need for treatment, (b) allocating evidence regarding the benefits and 
drawbacks of treatment, and (c) appraising patient values and inclinations (Ballard et al., 2017). 
Pokharel et al. (2016) suggest that eliminating barriers and implementing decision support tools 
has the potential to improve patient outcomes. Decision aids are an effective way for both 
patients and caregivers to conduct joint decision-making at the point of treatment (Ye et al., 
2018).  
Statin Choice Decision Aid 
The SCDA is designed to determine the patient’s 10-year ASCVD risk score and 
calculate the degree to which a statin will mitigate the risk (Inselman et al., 2016). It also 
graphically displays the risks and benefits associated with statin therapy. Clinicians are then able 
to share that information with the patient and provide a clear understanding of their health status. 
Upon checkout, the patient is given a handout summarizing the information covered during the 
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appointment (see Appendix B). After consulting with the provider, the patient is able to make an 
informed decision as to whether or not to start treatment with a statin or postpone their decision 
to a later time. 
Assessment 
 The clinic is a small family-owned primary care clinic in Laredo, Texas. The office is 
located in an administrative tower at Laredo Medical Center, the city’s largest acute care 
hospital. The clinic opened its doors in June of 2011. Together, Dr. G., an internal medicine 
physician, and his sister, a family medicine physician, opened the practice in June of 2011. 
Hours of operation are from Monday to Friday between the hours of 8 a.m. to 5 p.m. with 
laboratory service available at 7 a.m. The age range of patients treated are from 16 and 100 
years, with the average age being 60.  Personnel consists of one office manager, five medical 
assistants, three medical office assistants, two billers, and one information technology (IT) 
expert. There are no mid-level providers practicing at this facility. All staff members are fluent in 
both English and Spanish.  There are eight examination rooms equally divided among the 
physicians. Handicap accessibility is available throughout the facility. In September of 2015, the 
organization adopted eClinicalWorks, an electronic health charting system, for documentation 
purposes. Medication reconciliation is completed by the medical assistants during triage and 
verified by the physician during the clinical encounter. Laboratory studies done at the clinic are 
automatically populated into the electronic health record (EHR). For studies done elsewhere, 
results must be requested and manually scanned into the patient’s chart. Patient lab results are 
reviewed together with the physician at each follow-up visit.      
A sample of the clinic population done in a review of 100 charts showed that an 
overwhelming majority of the patients are Hispanic, and their primary language is Spanish. 
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Seventy-five percent of patients are Medicare and/or Medicaid beneficiaries, 22% are privately 
insured, and the remaining 3% are self-pay (see Table 1). Provider services focus on preventative 
care and chronic care management. The most common chronic illnesses treated are T2DM, 
hypertension, obesity, hyperlipidemia, and cardiovascular disease and patients usually presented 
with multiple comorbidities. Nonetheless, there are instances when patients would arrive in crisis 
requiring direct admission to the hospital or referral to the emergency department. In the event 
that a patient becomes hospitalized, Dr. G. assumes care on behalf of himself and his sister for all 
admissions. Patients are seen on a scheduled appointment-basis; however, walk-in appointments 
are also accepted when openings are available. Patients can expect an estimated wait time of 1 
hr. On average, the clinic sees 200-300 patients per week, with Dr. G. seeing an estimated 40-50 
patients per day. Referrals are normally made to specialists in urology, orthopedics, and 
nephrology for cases requiring a higher level of care. Education related to medication 
administration, such as anti-hyperglycemic injectables prescribed for patients with T2DM, is 
conducted by the medical assistants using a return demonstration approach. The visit summary 
which lists new or discontinued medications and outlines the plan of care is issued by the 
receptionist at checkout. 




 Number of Patients 
N = 100 
Gender 
     Male 





     Hispanic 
     Non-Hispanic White 
     African American 







     Medicare/Medicaid 
     HMO/PPO 






Organization’s Readiness for Change 
A pre-intervention chart audit conducted from September 6, 2019, to September 27, 
2019, surveyed the medical records of 100 patients with a diagnosis code of E11.9 (type II 
diabetes mellitus without complications). There was no report for any of the patients concerning 
a determined 10-year ASCVD risk evaluation. In addition, only 30% of patients had a statin 
prescription on board.  
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The results of the chart review were presented to Dr. G. in a face-to-face meeting. The 
needs assessment of the clinic highlighted a distinct variance between guideline 
recommendations and clinical practice. Due to the lack of consideration for the uniqueness of 
each patient's case, the primary provider expressed hesitation in adhering to the evidence-based 
guidance. The provider preferred treating each patient at an individual level, rather than 
prescribing statins based solely on guideline recommendations. A quality improvement (QI) 
initiative was suggested to align provider practice preferences and adherence to statin therapy 
guidelines using a decision aid tool.  
The clinic is enrolled in the Accountable Care Organization (ACO) program for quality 
improvement. The clinic has yet to meet the quality metrics for statin therapy guidelines, 
therefore reimbursement has not been attained. As part of the ACO, reimbursement is allocated 
in the form of a maximum bonus of 2% of earnings at the end of each year. These values are 
subject to change at any given time. In the event that a quality measure is not being met, clinics 
are penalized up to 4% of earnings within the same time frame. To be paid for the application of 
statin treatment, health care professionals must accurately record the applicable diagnosis code, 
prescribe a statin, and, if any, contraindications that exist. The goal of the QI project was to help 
the clinic meet the ACO benchmark by satisfying documentation regulations and supplementing 
clinic revenue.  
Project Identification 
Purpose 
The purpose of this quality-improvement project was to translate the evidence-based 
2018 ACC/AHA guidelines for cardiovascular disease prevention with statin therapy in patients 
with type 2 diabetes mellitus using the SCDA to support a patient-centered approach.  
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Objectives  
1. By April 27, 2020, the 2018 ACC/AHA guidelines for the primary prevention of 
cardiovascular disease for patients with T2DM were implemented into practice by 
prescribing statins for the appropriate patients.  
2. By April 27, 2020, the Statin Choice Decision Aid (SCDA) was used during eligible 
patients’ encounters as evidenced by documentation of the patient’s ASCVD risk score 
into the electronic charting system. 
Anticipated Aims 
1. Within 10 weeks of project implementation, 80% of eligible patients will be prescribed a 
statin based on the ACC/AHA guidelines. 
2. Within 10 weeks of project implementation, the provider will use the SCDA to document 
the 10-year ASCVD risk score in 90% of patient encounters. 
Summary and Strength of the Evidence 
A review of the literature supported the foundation of the QI project. Evidence provided 
insight into gaps that existed between clinical recommendations and a patient-centered approach 
to practice implementation. The search domains used to find publications were PubMed, 
CINAHL Complete, MEDLINE ProQuest, and ScienceDirect. Search terms included statins, 
type 2 diabetes mellitus, cardiovascular disease, shared decision-making, and decision aid. 
Included in the review of the literature were peer-reviewed articles published between 2015 and 
2019, with full-text available, and printed in English.  
Statin Therapy 
 The guidelines for primary prevention of ASCVD specified by the ACC/AHA aligned 
with the findings in the research studies. Lipid management with moderate-intensity statin 
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therapy was delineated as one of the superior methods for the reduction of ASCVD in at-risk 
populations. Despite the well-established evidence regarding the effectiveness of statins for the 
prevention of ASCVD, there is little evidence to show proof of provider adherence to treatment 
guidelines. Nineteen clinical trials performed by Chou et al. (2016) included a total of 71,344 
participants to compare the effects of statins to placebos. Results validated that statins were 
associated with a reduced risk of morbidity and mortality related to ASCVD events in adults 
without a prior history. A similar randomized controlled study by Mortensen et al. (2015) with 
37,892 patients corroborated that strict adherence to the appropriate intensity of statin based on 
risk rating was associated with significantly better patient outcomes. As indicated by the review 
of literature, most studies related to the efficacy of statins were systematic reviews classified as 
level one on the Hierarchy of Evidence. 
Statin Choice Decision Aid in Practice 
There was a minimal number of studies regarding the use of SCDA in practice. There 
were two articles found that explored the use of the SCDA in clinical practice. However, there 
was no evidence that the SCDA had ever been used among Hispanics. A descriptive study by Ye 
et al. (2018) on the opinions of 60 primary care providers suggested that the integration of a 
point-of-care decision support tool, such as the SCDA, into the EHR increases clinician 
cognizance and usage related to statins for primary prevention. Results implicated a definitive 
increase in Statin Choice Decision Aid usage because it was made easily accessible to the user. 
A comparable randomized controlled study by Perestelo-Pérez et al. (2016) evaluated the 
perceptions of the SCDA of 168 Spanish patients and 29 clinicians. Findings supported the 
efficacy of the SCDA as evidenced by increased patient knowledge of statins, risk perception, 
and satisfaction with the quality of the decision-making process. While decision aid tools are 
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readily available, the dearth of evidence suggests that they are still being underutilized in 
primary care.  
Shared Decision-Making 
A review of the evidence revealed that shared decision-making has not yet been adopted 
as the norm in clinical practice. A study by Montori et al. (2017) underlined barriers to the 
implementation of shared decision-making for internists. These included desire, time constraints, 
and lack of patient comprehension. There remains a need for support from stakeholders and 
healthcare leaders in order to hold shared decision-making as the standard in clinical practice. 
Adjusting quality measures to require the use of a decision aid may prompt physicians to adopt 
this patient-centered practice. On a more positive note, research conducted by Kashaf et al. 
(2017), elucidated the relationship between shared decision-making and improved patient 
knowledge, patient risk perception, and decision-making quality. Implications for practice 
included adopting the shared decision-making paradigm for better health outcomes. The majority 
of studies related to shared decision-making are descriptive studies categorized as level four on 
the Hierarchy of Evidence.  
Methods 
Implementation strategies were intended to be used only for the patients of the physician 
who served as the Doctor of Nursing Practice (DNP) student’s mentor. Interventions were 
selected to pilot guideline adherence in the clinic. The first step was to conduct an education 
session for the provider and clinic manager. The second step included generating an EHR alert to 
signal the provider of the need to perform a risk assessment for patients 40 to 75 years of age 
with a diagnosis of E11.9 (T2DM without complications). It was the physician’s personal 
preference to solely use the diagnostic code E11.9 to identify patients with a history of T2DM. 
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Educational Intervention 
One 30 min education session was held on the morning of Monday, February 10, 2020, 
for the provider and clinic manager. The clinic manager was included for the purpose of 
reinforcement and sustainability after completion of the QI project. The following information 
was conveyed in the form of a PowerPoint presentation which included: 1) 2018 ACC/AHA 
guidelines for the primary prevention of CVD for patients with T2DM, 2) statin options, 3) 
benefits of shared decision-making, and 4) operation of the SCDA. The PowerPoint presentation 
outline was distributed to the attendees and e-mailed to them for future reference.  
EHR Intervention 
The student partnered with the information technology systems expert to design an EHR 
alert used to flag the charts of patients meeting the following criteria: 
• 40-75 years of age 
• diagnosis of E11.9 (type II diabetes mellitus without complications) 
• no history of a statin prescription 
• no previously documented ASCVD risk score 
The alert was intended to encourage the provider to use the decision aid tool during the clinical 
encounter. A direct link to the decision aid tool was also made available in eClinicalWorks to 
enhance accessibility.  
Organizational Barriers and Facilitators 
 Organizational barriers to project implementation included the high volume of patients 
seen at the clinic on a daily basis. As a result, time constraints were anticipated to hinder the 
utilization of the SCDA during patient encounters. Another obstacle was the ability of the patient 
to reject statin therapy perhaps due to taking several drugs, or the aspect of adverse side effects. 
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Organizational facilitators included the support of the provider and his team for project 
implementation. This was expected to encourage adherence to the project implementation plan 
and solicited participation. Moreover, the provider had established long-standing, trusting 
relationships with his patients. Patients respect and customarily agree with the professional 
opinion of the provider. In appreciation of their involvement and cooperation, periodic gifts of 
gratitude (e.g. cookies, fruit, donuts) are provided to the staff. 
Ethical Considerations 
Ethical considerations for project implementation were the privacy of patients’ medical 
records. No identifiable patient information was used for data collection. Data were recorded 
on an Excel worksheet and the file was stored on a secure USB drive kept in a locked cabinet 
located inside the clinic manager’s office accessible only to the office manager, physician, and 
the DNP student. The doctoral student conducting the QI project completed a Health Insurance 
Portability and Accountability Act and Collaborative Institutional Training Initiative training 
certification prior to initiation.  
Letter of Support  
The management at the practice provided a letter of support expressing its approval and 
support for implementation of the QI project (Appendix C). 
Evaluation 
A 10-week retrospective review of data obtained from the medical reports was used to 
evaluate project outcomes. Inclusive criteria for data collection consisted of adults 40 to 75 years
of age, with a diagnosis of type 2 diabetes, who have a serum LDL-C of greater than or equal to 
70, and who were not on a statin regimen. Corroboration of Clinical summaries were assessed 
for provider documentation of an ASCVD risk score and evidence that a statin prescription was 
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sent to pharmacy. This information was located in the “assessment” section of the clinical note. 
The SCDA Patients had the option of accepting, declining, or deferring statin therapy.  
Results 
Results were obtained from the charts of all patients ages 40 to 75 years with a diagnosis 
of type 2 diabetes (E11.9) seen within the 10-week implementation period. A total of 100 
patient charts were reviewed between April 28, 2020 and May 5, 2020. Of the 100 patient 
charts, data showed 42 were female and 58 were male. Atorvastatin, rosuvastatin, and 
simvastatin were prescribed the most because of cost-effectiveness.   
The first aim was that 80% of eligible patients would be prescribed a statin based on 
the ACC/AHA guidelines. The percentage of statins prescribed increased from 30% to 80%. In 
spite of the challenges posed by the COVID-19 pandemic, 82% of patients were given a statin, 
according to the findings (see Table 2). The number of statins prescribed was the lowest during 
the transition to telemedicine which occurred during week 7 (see Figure 1). 
Table 2 
Prescription of Statins 
Yes No Total 
Pre-Intervention 30 70 100 
Post-Intervention 82 18 100 
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Figure 1  
Number of Statins Prescribed  
 
The second aim was that the provider would use the SCDA to document the 10-year 
ASCVD risk score in 90% of patient encounters. Although statins were being prescribed, only 
75% of charts displayed evidence of an ASCVD risk score assessment which fell short of the 
initial goal of 90% (see Table 3). The final 4 weeks of the implementation affected by the 
COVID-19 pandemic had the least amount of documentation. During this time, only 1 out of the 
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Statins Prescribed Post-Intervention (n = 82)
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Table 3 
10-Year ASCVD Risk Score Documentation 
 Yes No Total 
Pre-Intervention 0 100 100 
Post-Intervention  58 (75%) 19 (25%) 77 
 
Figure 2  
Documentation of 10-Year ASCVD Risk Score  
 
Discussion 
The dramatic rise in the number of statin prescriptions proved to be the biggest 
achievement of the DNP initiative. Eighty-two out of 100 patients reviewed received a statin 
prescription which exceeded expectations. Another positive outcome was the overall 
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Documented 10-Year ASCVD Risk Score Post Intervention (n = 58)
Number of Charts
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risk scores were never documented. Results indicated that the provider’s rate of documentation 
grew from 0% to 75%. Although the goal of 90% was not met, there was a steady increase 
during the time prior to the pandemic. The strength of this project was that statin prescription 
practice was affiliated with reimbursement opportunity. One of the objectives of the QI project 
was to use the SCDA during the clinical encounter to implement clinical guidelines using a 
patient-centered approach. This finding is aligned by a systematic review of six randomized 
controlled trials by Serrano and colleagues (2016) which evaluated the impact of shared 
decision-making in the care of individuals with diabetes. The literature revealed the efficacy of 
evidence-based decision aids to support shared decision-making as evidenced by an increase in 
the patient’s knowledge, satisfaction, and risk awareness. Although it is beyond the scope of this 
project, it would be of interest to determine if the level of patient knowledge, satisfaction, and 
risk awareness was affected by the use of the SCDA.  
Limitations 
Time constraints limited the use of the SCDA during the clinical encounter as expected. 
As a result of the pandemic, in-person appointments were replaced by telephone calls which 
weakened shared decision-making. Research by Neville (2018) suggests that patient 
relationships are often damaged as a result of telehealth and the lack of human interaction (p. 4).  
The effectiveness and usage of the decision aid tool was hindered by the lack of face-to-face 
interaction and provider presence. Likewise, if the patient reported an acute health issue, the 
provider’s attention was sidetracked from assessing the patient’s ASCVD risk status to 
addressing the active problem.  
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COVID-19 
The outbreak of the coronavirus disease 2019, commonly referred to as COVID-19, 
swept the community in late March. The COVID-19 pandemic produced unforeseen limitations 
during the latter part of the implementation phase. A shelter-in-place ordinance was enforced by 
City of Laredo officials on March 31, 2020, and a state of emergency was declared shortly 
afterward. Times of duress initiated a hurried transition to telemedicine that coincided with the 
last 4 weeks of the QI project. Consequently, all patient consultations were performed via 
telephone calls without video conference. Thirty min prior to the scheduled appointment time, 
the patient was initially contacted by a medical assistant for triage and documentation of the 
chief complaint. The provider then reviewed the chart and contacted the patient within 30 min. 
This made instituting a collaborative approach to making treatment decisions difficult because 
of the absence of the provider’s presence. In addition, the patients were not able to jointly view 
the computer screen which revealed the ASCVD information with the provider, nor could they 
receive the educational material. The pandemic caused an increase in the number of 
appointment cancellations and patients became reluctant to have lab work drawn for fear of 
potential exposure to COVID-19. In addition, there were 19 patients who did not have lab results 
available for review therefore they were not included in the project sample.  
Recommendations for Sustainability 
For intervention continuation, the clinic manager was assigned the responsibility of 
verifying that the EHR alert system is operational on a weekly basis. Issuing a monthly progress 
report that displays the number of patients prescribed a statin and the amount of potential 
reimbursement lost may be beneficial. Furthermore, the use of the SCDA to promote statin 
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therapy can be expanded to include the other provider. Soliciting the support of the medical 
assistants to promote the project would also be of benefit.   
Implications for Practice 
Keeping patients healthy and out of the hospital while meeting quality metrics can 
potentially generate up to $50,000 per year in additional revenue. Increased shared decision-
making may improve patient engagement during the clinical encounter and adherence to the 
medication regimen. Likewise, increased revenue is related to better statin prescription practices. 
In the future, project permanence will help the provider avoid a penalty for failure to meet the 
benchmark set by the ACO benchmark, and instead receive financial reward. 
Role of the Nurse Practitioner with DNP Degree 
The Doctor of Nursing Practice degree provides nurse practitioners with the skills 
necessary to assume leadership roles and practice at the highest level in order to improve 
patients’ quality of life (Almasy & Champion, 2016). The DNP Essentials are the foundation of 
practice for doctoral-prepared nurse practitioners. It is the DNP’s responsibility to interpret and 
translate the evidence and apply recommendations for use in practice. The DNP-prepared nurse 
practitioner must also be knowledgeable in the expert care and management of patients with a 
variety of conditions. This project was a true application of the DNP Essentials into practice. It 
fostered interprofessional teamwork and communication for the purpose of improving health 
outcomes of individuals with T2DM.  In addition, the application of telemedicine aligned with 
DNP Essential IV which is directly related to the use of technology for the transformation of 
healthcare. Clinical practice was changed by the provider calculating 10-year ASCVD risk 
scores and prescribing statins to eligible patients in an effort to effectively manage cholesterol 
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levels.  The project also helped to enhance the provider’s cognizance of the adverse effects of 
cardiovascular disease for patients with Type 2 Diabetes.  
Patients with type 2 diabetes mellitus remain at high risk for developing cardiovascular 
disease. It is imperative that healthcare providers take the proper measures supported by quality 
evidence to aid in the protection of their patients. By assessing the ASCVD risk score and 
prescribing statin therapy for those at high-risk, further development of comorbidities can be 
avoided. Moreover, primary care providers must remain current on practice guidelines and best 
practice standards. When discussing ASCVD prevention, a shared decision-making approach to 
treatment may help improve the quality of care provided in the primary care setting. During the 
clinical encounter, clinicians should strive to earn patients’ trust in order to attain measurable 
results. The DNP prepared APRN is equipped with the knowledge and skills to help translate 
innovative evidence-based guidelines into practice. 
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